FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4366831820> ?p ?o ?g. }

• W4366831820 abstract "Abstract Background/Aims Guselkumab, a human monoclonal antibody targeting the interleukin-23 p19 subunit, demonstrated joint and skin efficacy in patients with PsA in the Phase III DISCOVER-1/-2 trials. MDA, a multi-domain composite outcome, is a clinically relevant measure of therapeutic response in PsA. However, response dynamics and the effect of individual domains on achieving MDA are not well understood. This analysis aimed to characterise MDA response clusters according to domain changes over time and identify potential baseline predictors in patients with PsA receiving guselkumab. Methods Data from bio-naïve patients with active PsA receiving guselkumab 100 mg every 4 or 8 weeks were pooled across DISCOVER-1/-2. Unsupervised machine learning using the time-series K-means clustering algorithm was performed to identify clusters according to MDA domain responses over 52 weeks. Missing data were not imputed. Results This analysis included 571 of 669 patients receiving guselkumab and distinguished four response clusters (C1-4; Table 1). Mean age and body mass index were similar across clusters; C3 had a lower proportion of female patients vs. other clusters. Relative to C3, a high burden of baseline disease was observed in C4 across clinical measures and PROs, and across PROs only in C2. Through Week 52, mean values for all MDA domains showed continuous improvement across clusters (Table 1). MDA response rates were highest in C3, in which all individual domain thresholds were rapidly approached, and lowest in C4. In C1 and C2, improvement in clinical measures paralleled that of C3; both met the PASI threshold and showed substantial reduction in SJC. PROs appeared to take longer to improve but did so earlier in C1 than C2. Improvements were slowest in C4, though still substantial given the high baseline disease burden. Conclusion Machine learning differentiated four clusters of patients with PsA receiving guselkumab based on response patterns in individual MDA domains. Response may differ due to baseline disease burden, especially in patients with high pain, PtGA and functional disability scores. These results offer an innovative, complementary approach to identifying treatment response patterns across diverse clusters of bio-naïve patients with PsA, which may facilitate clinical decision-making. Disclosure A. Zabotti: Member of speakers’ bureau; AbbVie, Amgen, Janssen, Lilly, Novartis and UCB. Grants/research support; Novartis. S. Ohrndorf: Other; Speaker fees or travel expense reimbursements from AbbVie, BMS, Janssen, Novartis and Pfizer. W. Tillett: Other; Research funding, consulting, speaker fees and/or honoraria from AbbVie, Amgen, Celgene, GlaxoSmithKline, Janssen, Lilly, MSD, Novartis, Pfizer and UCB. M. Neuhold: Other; Former employee of Janssen and is now an employee of Takeda Pharmaceuticals International AG. M. van Speybroeck: Shareholder/stock ownership; Employee of Janssen and owns stocks in Johnson & Johnson. E. Theander: Other; Former employee of Janssen. C. Contré: Other; Former employee of Janssen and is now an employee of Chiesi. M. Sharaf: Shareholder/stock ownership; Employee of Janssen and owns stocks in Johnson & Johnson. M. Shawi: Shareholder/stock ownership; Employee of Janssen and owns stocks in Johnson & Johnson. M. Perate: Shareholder/stock ownership; Employee of Janssen and owns stocks in Johnson & Johnson. A. Kollmeier: Shareholder/stock ownership; Employee of Janssen and owns stocks in Johnson & Johnson. P. Richette: Other; Received fees from AbbVie, Amgen, Celgene, Janssen, Lilly, MSD, Novartis, Pfizer and UCB." @default.
• W4366831820 created "2023-04-25" @default.
• W4366831820 creator A5010193939 @default.
• W4366831820 creator A5010559526 @default.
• W4366831820 creator A5011620868 @default.
• W4366831820 creator A5013138894 @default.
• W4366831820 creator A5021001959 @default.
• W4366831820 creator A5031141146 @default.
• W4366831820 creator A5046382872 @default.
• W4366831820 creator A5046697491 @default.
• W4366831820 creator A5053353962 @default.
• W4366831820 creator A5062337812 @default.
• W4366831820 creator A5080060775 @default.
• W4366831820 creator A5084376077 @default.
• W4366831820 date "2023-04-01" @default.
• W4366831820 modified "2023-10-04" @default.
• W4366831820 title "P180 Minimal disease activity response patterns in bio-naïve patients with psoriatic arthritis treated with guselkumab: a machine learning analysis" @default.
• W4366831820 doi "https://doi.org/10.1093/rheumatology/kead104.221" @default.
• W4366831820 hasPublicationYear "2023" @default.
• W4366831820 type Work @default.
• W4366831820 citedByCount "0" @default.
• W4366831820 crossrefType "journal-article" @default.
• W4366831820 hasAuthorship W4366831820A5010193939 @default.
• W4366831820 hasAuthorship W4366831820A5010559526 @default.
• W4366831820 hasAuthorship W4366831820A5011620868 @default.
• W4366831820 hasAuthorship W4366831820A5013138894 @default.
• W4366831820 hasAuthorship W4366831820A5021001959 @default.
• W4366831820 hasAuthorship W4366831820A5031141146 @default.
• W4366831820 hasAuthorship W4366831820A5046382872 @default.
• W4366831820 hasAuthorship W4366831820A5046697491 @default.
• W4366831820 hasAuthorship W4366831820A5053353962 @default.
• W4366831820 hasAuthorship W4366831820A5062337812 @default.
• W4366831820 hasAuthorship W4366831820A5080060775 @default.
• W4366831820 hasAuthorship W4366831820A5084376077 @default.
• W4366831820 hasBestOaLocation W43668318201 @default.
• W4366831820 hasConcept C126322002 @default.
• W4366831820 hasConcept C143998085 @default.
• W4366831820 hasConcept C2776260265 @default.
• W4366831820 hasConcept C2779134260 @default.
• W4366831820 hasConcept C71924100 @default.
• W4366831820 hasConceptScore W4366831820C126322002 @default.
• W4366831820 hasConceptScore W4366831820C143998085 @default.
• W4366831820 hasConceptScore W4366831820C2776260265 @default.
• W4366831820 hasConceptScore W4366831820C2779134260 @default.
• W4366831820 hasConceptScore W4366831820C71924100 @default.
• W4366831820 hasIssue "Supplement_2" @default.
• W4366831820 hasLocation W43668318201 @default.
• W4366831820 hasOpenAccess W4366831820 @default.
• W4366831820 hasPrimaryLocation W43668318201 @default.
• W4366831820 hasRelatedWork W2146291496 @default.
• W4366831820 hasRelatedWork W2315626382 @default.
• W4366831820 hasRelatedWork W2330995418 @default.
• W4366831820 hasRelatedWork W2357437675 @default.
• W4366831820 hasRelatedWork W2756411137 @default.
• W4366831820 hasRelatedWork W2895953343 @default.
• W4366831820 hasRelatedWork W2943986375 @default.
• W4366831820 hasRelatedWork W2966231411 @default.
• W4366831820 hasRelatedWork W3162953628 @default.
• W4366831820 hasRelatedWork W3215971232 @default.
• W4366831820 hasVolume "62" @default.
• W4366831820 isParatext "false" @default.
• W4366831820 isRetracted "false" @default.
• W4366831820 workType "article" @default.